Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Osteoporosis Reports
Published in: Current Osteoporosis Reports 1/2020

Open Access 01-02-2020 | Care | QUALITY OF CARE IN OSTEOPOROSIS (S SILVERMAN AND J CURTIS, SECTION EDITORS)

General and Specific Considerations as to why Osteoporosis-Related Care Is Often Suboptimal

Authors: Elizabeth M Curtis, Stephen Woolford, Claire Holmes, Cyrus Cooper, Nicholas C Harvey

Published in: Current Osteoporosis Reports | Issue 1/2020

Login to get access

Abstract

Purpose of Review

The assessment of fracture risk and use of antiosteoporosis medications have increased greatly over the last 20–30 years. However, despite this, osteoporosis care remains suboptimal worldwide. Even in patients who have sustained a fragility fracture, fewer than 20% actually receive appropriate antiosteoporosis therapy in the year following the fracture. There is also evidence that treatment rates have declined substantially in the last 5–10 years, in many countries. The goal of this article is to consider the causes for this decline and consider how this situation could be remedied.

Recent Findings

A number of possible reasons, including the lack of prioritisation of osteoporosis therapy in ageing populations with multimorbidity, disproportionate concerns regarding the rare side effects of anti-resorptives and adverse changes in reimbursement in the USA, have been identified as contributing factors in poor osteoporosis care.

Summary

Improved secondary prevention strategies; screening measures (primary prevention) and appropriate, cost-effective guideline and treatment threshold development could support the optimisation of osteoporosis care and prevention of future fractures.
Literature
1.
Harvey NC, McCloskey EV, Mitchell PJ, Dawson-Hughes B, Pierroz DD, Reginster JY, et al. Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures. Osteoporos Int. 2017;28(5):1507–29.PubMedPubMedCentral
2.
Giangregorio L, Papaioannou A, Cranney A, Zytaruk N, Adachi JD. Fragility fractures and the osteoporosis care gap: an international phenomenon. Semin Arthritis Rheum. 2006;35(5):293–305.PubMed
3.
Kanis JA, Svedbom A, Harvey N, McCloskey EV. The osteoporosis treatment gap. J Bone Miner Res. 2014;29(9):1926–8.PubMed
4.
Kanis JA, Johansson H, Oden A, Cooper C, McCloskey EV. Worldwide uptake of FRAX. Arch Osteoporos. 2014;9(1):166.PubMed
5.
Kanis JA, Oden A, McCloskey EV, Johansson H, Wahl DA, Cooper C. A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int. 2012;23(9):2239–56.PubMedPubMedCentral
6.
Solomon DH, Johnston SS, Boytsov NN, McMorrow D, Lane JM, Krohn KD. Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res. 2014;29(9):1929–37.PubMed
7.
van der Velde RY, Wyers CE, Teesselink E, Geusens PP, van den Bergh JP, de Vries F, et al. Trends in oral anti-osteoporosis drug prescription in the United Kingdom between 1990 and 2012: variation by age, sex, geographic location and ethnicity. Bone. 2016;94:50–5.PubMedPubMedCentral
8.
Klop C, Welsing PM, Cooper C, Harvey NC, Elders PJ, Bijlsma JW, et al. Mortality in British hip fracture patients, 2000-2010: a population-based retrospective cohort study. Bone. 2014;66:171–7.PubMed
9.
• Hawley S, Leal J, Delmestri A, Prieto-Alhambra D, Arden NK, Cooper C, et al. Anti-osteoporosis medication prescriptions and incidence of subsequent fracture among primary hip fracture patients in England and Wales: an interrupted time-series analysis. J Bone Miner Res. 2016;31(11):2008–15 A paper demonstrating the importance of national guidance and availability of cheaper generic antiosteoporosis medications on prescribing and subsequent fractures. PubMed
10.
Shah A, Prieto-Alhambra D, Hawley S, Delmestri A, Lippett J, Cooper C, et al. Geographic variation in secondary fracture prevention after a hip fracture during 1999-2013: a UK study. Osteoporos Int. 2017;28(1):169–78.PubMed
11.
Greenspan SL, Wyman A, Hooven FH, Adami S, Gehlbach S, Anderson FA Jr, et al. Predictors of treatment with osteoporosis medications after recent fragility fractures in a multinational cohort of postmenopausal women. J Am Geriatr Soc. 2012;60(3):455–61.PubMedPubMedCentral
12.
Svedbom A, Hernlund E, Ivergard M, Compston J, Cooper C, Stenmark J, et al. Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos. 2013;8(1–2):137.PubMedPubMedCentral
13.
van der Velde RY, Wyers CE, Teesselink E, Geusens PP, van den Bergh JP, de Vries F, et al. Trends in oral anti-osteoporosis drug prescription in the United Kingdom between 1990 and 2012: variation by age, sex, geographic location and ethnicity. Bone. 2017;94:50–5.PubMed
14.
Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden : a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2013;8(1–2):136.PubMedPubMedCentral
15.
Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013;24(1):23–57.PubMed
16.
Lekamwasam S, Adachi JD, Agnusdei D, Bilezikian J, Boonen S, Borgstrom F, et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int. 2012;23(9):2257–76.PubMed
17.
Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, Harvey N, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2017;12(1):43.PubMedPubMedCentral
18.
Diez-Perez A, Hooven FH, Adachi JD, Adami S, Anderson FA, Boonen S, et al. Regional differences in treatment for osteoporosis. The global longitudinal study of osteoporosis in women (GLOW). Bone. 2011;49(3):493–8.PubMedPubMedCentral
19.
Martin-Merino E, Huerta-Alvarez C, Prieto-Alhambra D, Alvarez-Gutierrez A, Montero-Corominas D. Secular trends of use of anti-osteoporotic treatments in Spain: a population-based cohort study including over 1.5million people and more than 12years of follow-up. Bone. 2017;105:292–8.PubMed
20.
Abrahamsen B, Skjodt MK, Vestergaard P. Hip fracture rates and time trends in use of anti-osteoporosis medications in Denmark for the period 2005 to 2015: missed opportunities in fracture prevention. Bone. 2019;120:476–81.PubMed
21.
Jha S, Wang Z, Laucis N, Bhattacharyya T. Trends in media reports, oral bisphosphonate prescriptions, and hip fractures 1996-2012: an ecological analysis. J Bone Miner Res. 2015;30(12):2179–87.PubMed
22.
Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP, Binkley N, et al. Interpretation and use of FRAX in clinical practice. Osteoporos Int. 2011;22(9):2395–411.PubMed
23.
Kanis JA, Harvey NC, Cooper C, Johansson H, Oden A, McCloskey EV. A systematic review of intervention thresholds based on FRAX: a report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos. 2016;11(1):25.PubMedPubMedCentral
24.
Oden A, McCloskey EV, Kanis JA, Harvey NC, Johansson H. Burden of high fracture probability worldwide: secular increases 2010-2040. Osteoporos Int. 2015;26(9):2243–8.PubMed
25.
Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):743–800.
26.
Harvey N, Dennison E, Cooper C. Osteoporosis: impact on health and economics. Nat Rev Rheumatol. 2010;6(2):99–105.PubMed
27.
Austin PC, Tu JV, Ko DT, Alter DA. Factors associated with the use of evidence-based therapies after discharge among elderly patients with myocardial infarction. CMAJ. 2008;179(9):901–8.PubMedPubMedCentral
28.
Siris ES, Gehlbach S, Adachi JD, Boonen S, Chapurlat RD, Compston JE, et al. Failure to perceive increased risk of fracture in women 55 years and older: the global longitudinal study of osteoporosis in women (GLOW). Osteoporos Int. 2011;22(1):27–35.PubMed
29.
Järvinen TL, Michaëlsson K, Jokihaara J, Collins GS, Perry TL, Mintzes B, et al. Overdiagnosis of bone fragility in the quest to prevent hip fracture. BMJ. 2015;350:h2088.PubMed
30.
Järvinen TLN, Michaëlsson K, Aspenberg P, Sievänen H. Osteoporosis: the emperor has no clothes. J Intern Med. 2015;277(6):662–73.PubMedPubMedCentral
31.
Compston J. Overdiagnosis of osteoporosis: fact or fallacy? Osteoporos Int. 2015;26(8):2051–4.PubMed
32.
Cipriani C, Pepe J, Minisola S, Lewiecki EM. Adverse effects of media reports on the treatment of osteoporosis. J Endocrinol Investig. 2018;41(12):1359–64.
33.
Peeters G, Tett SE, Duncan EL, Mishra GD, Dobson AJ. Osteoporosis medication dispensing for older Australian women from 2002 to 2010: influences of publications, guidelines, marketing activities and policy. Pharmacoepidemiol Drug Saf. 2014;23(12):1303–11.PubMed
34.
Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016;31(1):16–35.PubMed
35.
Farmer C, Fenu E, O'Flynn N, Guthrie B. Clinical assessment and management of multimorbidity: summary of NICE guidance. BMJ. 2016;354:i4843.PubMed
36.
Black DM, Rosen CJ. Clinical Practice. Postmenopausal Osteoporosis. N Engl J Med. 2016;374(3):254–62.PubMed
37.
Gedmintas L, Solomon DH, Kim SC. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res. 2013;28(8):1729–37.PubMed
38.
• Black DM, Abrahamsen B, Bouxsein ML, Einhorn T, Napoli N. Atypical femur fractures: review of epidemiology, relationship to bisphosphonates, prevention, and clinical management. Endocr Rev. 2019;40(2):333–68 A key, up to date review on atypical femoral fractures, how to prevent and manage them.
39.
Brown JP, Roux C, Törring O, Ho P-R, Beck Jensen J-E, Gilchrist N, et al. Discontinuation of denosumab and associated fracture incidence: analysis from the fracture reduction evaluation of denosumab in osteoporosis every 6 months (FREEDOM) trial. J Bone Miner Res. 2013;28(4):746–52.PubMed
40.
Abrahamsen B, Eiken P, Prieto-Alhambra D, Eastell R. Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study. Bmj. 2016;353:i3365.PubMedPubMedCentral
41.
•• Dennison EM, Cooper C, Kanis JA, Bruyere O, Silverman S, McCloskey E, et al. Fracture risk following intermission of osteoporosis therapy. Osteoporos Int. 2019;30(9):1733–43. A new systematic review on intermission of osteoporosis therapy, known as “treatment holidays”, led by the International Osteoporosis Foundation. PubMed
42.
Kanis JA, Borgstrom F, Compston J, Dreinhofer K, Nolte E, Jonsson L, et al. SCOPE: a scorecard for osteoporosis in Europe. Arch Osteoporos. 2013;8:144.PubMedPubMedCentral
43.
Overman RA, Farley JF, Curtis JR, Zhang J, Gourlay ML, Deal CL. DXA utilization between 2006 and 2012 in commercially insured younger postmenopausal women. J Clin Densitom. 2015;18(2):145–9.PubMedPubMedCentral
44.
Lewiecki EM, Adler RA, Curtis J, Gagel RF, Saag KG, Singer A, et al. Hip fractures and declining DXA testing: at a breaking point? J Bone Miner Res. 2016. American Society for Bone and Mineral Research Annual Scientific Meeting (Abstract 1077).
45.
Grover ML, Edwards FD, Chang YH, Cook CB, Behrens MC, Dueck AC. Fracture risk perception study: patient self-perceptions of bone health often disagree with calculated fracture risk. Womens Health Issues. 2014;24(1):e69–75.PubMed
46.
Gregson CL, Dennison EM, Compston JE, Adami S, Adachi JD, Anderson FA Jr, et al. Disease-specific perception of fracture risk and incident fracture rates: GLOW cohort study. Osteoporos Int. 2014;25(1):85–95.PubMed
47.
Eisman JA, Bogoch ER, Dell R, Harrington JT, McKinney RE Jr, McLellan A, et al. Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention. J Bone Miner Res. 2012;27(10):2039–46.PubMed
48.
Mitchell PJ. Best practices in secondary fracture prevention: fracture liaison services. Curr Osteoporos Rep. 2013;11(1):52–60.PubMed
49.
• Drew S, Judge A, Cooper C, Javaid MK, Farmer A, Gooberman-Hill R. Secondary prevention of fractures after hip fracture: a qualitative study of effective service delivery. Osteoporos Int. 2016;27(5):1719–27 A paper discussing ways of developing best models of secondary fracture prevention after hip fracture, through structured interviewing of health professionals. PubMedPubMedCentral
50.
Akesson K, Marsh D, Mitchell PJ, McLellan AR, Stenmark J, Pierroz DD, et al. Capture the fracture: a best practice framework and global campaign to break the fragility fracture cycle. Osteoporos Int. 2013;24(8):2135–52.PubMedPubMedCentral
51.
Javaid MK, Kyer C, Mitchell PJ, Chana J, Moss C, Edwards MH, et al. Effective secondary fracture prevention: implementation of a global benchmarking of clinical quality using the IOF capture the fracture(R) best practice framework tool. Osteoporos Int. 2015;26(11):2573–8.PubMed
52.
Mitchell P, Akesson K, Chandran M, Cooper C, Ganda K, Schneider M. Implementation of models of care for secondary osteoporotic fracture prevention and orthogeriatric models of care for osteoporotic hip fracture. Best Pract Res Clin Rheumatol. 2016;30(3):536–58.PubMed
53.
Cooper C, Atkinson EJ, O'Fallon WM, Melton LJ. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res. 1992;7(2):221–7.PubMed
54.
Clark EM, Gould V, Morrison L, Ades AE, Dieppe P, Tobias JH. Randomized controlled trial of a primary care-based screening program to identify older women with prevalent osteoporotic vertebral fractures: cohort for skeletal health in Bristol and Avon (COSHIBA). J Bone Miner Res. 2012;27(3):664–71.PubMed
55.
Clark EM, Gooberman-Hill R, Peters TJ. Using self-reports of pain and other variables to distinguish between older women with back pain due to vertebral fractures and those with back pain due to degenerative changes. Osteoporos Int. 2016;27(4):1459–67.PubMed
56.
Oei L, Koromani F, Breda SJ, Schousboe JT, Clark EM, van Meurs JB, et al. Osteoporotic vertebral fracture prevalence varies widely between qualitative and quantitative radiological assessment methods: the Rotterdam study. J Bone Miner Res. 2018;33(4):560–8.PubMed
57.
Muehlematter UJ, Mannil M, Becker AS, Vokinger KN, Finkenstaedt T, Osterhoff G, et al. Vertebral body insufficiency fractures: detection of vertebrae at risk on standard CT images using texture analysis and machine learning. Eur Radiol. 2019;29(5):2207–17.PubMed
58.
Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359–81.PubMedPubMedCentral
59.
Lekamwasam S, Adachi JD, Agnusdei D, Bilezikian J, Boonen S, Borgstrom F, et al. An appendix to the 2012 IOF-ECTS guidelines for the management of glucocorticoid-induced osteoporosis. Arch Osteoporos. 2012;7(1–2):25–30.PubMed
60.
Shepstone L, Fordham R, Lenaghan E, Harvey I, Cooper C, Gittoes N, et al. A pragmatic randomised controlled trial of the effectiveness and cost-effectiveness of screening older women for the prevention of fractures: rationale, design and methods for the SCOOP study. Osteoporos Int. 2012;23(10):2507–15.PubMed
61.
•• Shepstone L, Lenaghan E, Cooper C, Clarke S, Fong-Soe-Khioe R, Fordham R, et al. Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial. Lancet. 2018;391(10122):741–7 A randomised controlled trial of community screening for fracture risk in UK women demonstrating a reduction in hip fractures in screened women.
62.
McCloskey E, Johansson H, Harvey NC, Shepstone L, Lenaghan E, Fordham R, et al. Management of patients with high baseline hip fracture risk by FRAX reduces hip fractures-a post hoc analysis of the SCOOP study. J Bone Miner Res. 2018;33(6):1020–6.PubMed
63.
Turner DA, Khioe RFS, Shepstone L, Lenaghan E, Cooper C, Gittoes N, et al. The cost-effectiveness of screening in the community to reduce osteoporotic fractures in older women in the UK: economic evaluation of the SCOOP study. J Bone Miner Res. 2018;33(5):845–51.PubMed
64.
Rubin KH, Rothmann MJ, Holmberg T, Hoiberg M, Moller S, Barkmann R, et al. Effectiveness of a two-step population-based osteoporosis screening program using FRAX: the randomized risk-stratified osteoporosis strategy evaluation (ROSE) study. Osteoporos Int. 2018;29(3):567–78.PubMed
65.
Viswanathan M, Reddy S, Berkman N, Cullen K, Middleton JC, Nicholson WK, et al. Screening to prevent osteoporotic fractures: updated evidence report and systematic review for the US preventive services task force USPSTF evidence report: screening to prevent osteoporotic FracturesUSPSTF evidence report: screening to prevent osteoporotic fractures. JAMA. 2018;319(24):2532–51.PubMed
66.
NICE. TA464: bisphosphonates for treating osteoporosis. London: National Institute for Health and Care Excellence; 2017.
67.
Harvey NC, McCloskey E, Kanis J, Compston J, Cooper C. Bisphosphonates in osteoporosis: NICE and easy? Lancet. 2017;390(10109):2243–4.
68.
Harvey NC, McCloskey E, Kanis JA, Compston J, Cooper C. Cost-effective but clinically inappropriate: new NICE intervention thresholds in osteoporosis (technology appraisal 464). Osteoporos Int. 2018;29(7):1511–3.PubMedPubMedCentral
69.
•• Khosla S, Hofbauer LC. Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol. 2017;5(11):898–907 An important review article addressing the problem of osteoporosis treatment acceptance amongst patients and strategies to address this.
70.
•• Harvey NC, McCloskey E. Gaps and solutions in bone health: a global framework for improvement. 2016. https://​www.​iofbonehealth.​org/​thematicreport-2016. A report produced by the International Osteoporosis Foundation to describe 10 key care gaps which are hindering osteoporosis treatment and fracture prevention worldwide.
71.
Harvey NCW, McCloskey EV, Rizzoli R, Kanis JA, Cooper C, Reginster J-Y. Osteoporosis: treatment gaps and health economics. In: Huhtaniemi I, Martini L, editors. Encyclopedia of endocrine diseases. Second ed. Oxford: Academic Press; 2019. p. 288–95.
72.
Liu J, Curtis EM, Cooper C, Harvey NC. State of the art in osteoporosis risk assessment and treatment. J Endocrinol Investig. 2019;42(10):1149–64.
Metadata
Title
General and Specific Considerations as to why Osteoporosis-Related Care Is Often Suboptimal
Authors
Elizabeth M Curtis
Stephen Woolford
Claire Holmes
Cyrus Cooper
Nicholas C Harvey
Publication date
01-02-2020
Publisher
Springer US
Published in
Current Osteoporosis Reports / Issue 1/2020
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI
https://doi.org/10.1007/s11914-020-00566-7

Other articles of this Issue 1/2020

Current Osteoporosis Reports 1/2020 Go to the issue

Imaging (F. Wehrli and T. Lang, Section Editors)

MRI Assessment of Bone Marrow Composition in Osteoporosis

Osteoimmunology (M Nakamura and J Lorenzo, Section Editors)

The Interrelationship Between Diabetes, IL-17 and Bone Loss

Osteoimmunology (M Nakamura and J Lorenzo, Section Editors)

The Effects of Sclerostin on the Immune System

Osteocytes (J Klein-Nulend and J Delgado Calle, Section Editors)

Osteocyte-Mediated Translation of Mechanical Stimuli to Cellular Signaling and Its Role in Bone and Non-bone-Related Clinical Complications

Biomechanics (G Niebur, J Wallace, Section Editors)

In Vivo Assessment of Cortical Bone Fragility

Muscle and Bone (L. Bonewald and M. Hamrick, Section Editors)

Complicated Muscle-Bone Interactions in Children with Cerebral Palsy